Active Substance: Dexlansoprazole.
Overview
Welcome to Dwaey, specifically on DEXILANT 30mg page.
This medicine contains an important and useful components, as it consists of
Dexlansoprazoleis available in the market in concentration
Dexlansoprazole
Hepatic impairment. Gastric malignancy should be ruled out. Pregnancy and lactation. Lactation: Not known whether distributed into breast milk; discontinue nursing or drug
Oesophagitis, Gastro-oesophageal reflux disease (GERD)
Hypersensitivity.
1-10% Diarrhea (5%),Abdominal pain (4%),Nausea (3%),URI (2-3%),Vomiting (1-2%),Flatulence (1%) <1% (Selected) Arrhythmia,Bradycardia,Barrett's esophagus,DVT,Dyspnea,Hepatomegaly,Hypertension,Paresthesia,Rectal hemorrhage,Vulvovaginal infection
2
R-enantiomer of lansoprazole; PPI; binds to H+/K+-exchanging ATPase (proton pump) in gastric parietal cells, resulting in blockage of acid secretion.Dual release formulation.
Increased risk of hypomagnesaemia w/ diuretics and digoxin. May decrease plasma concentration of erlotinib, dasatinib and lapatinib. May decrease the bioavailability of itraconazole and ketoconazole. May increase plasma concentration of cilostazol and methotrexate. Reduced bioavailability w/ antacids and sucralfate. Potentially Fatal: May decrease serum levels and pharmacological effects of rilpivirine and atazanavir.
Information not available